LivaNova plc Aktie
LivaNova plc Aktie
Eine klare Tendenz zu Buy-Einschätzungen bei LivaNova plc, ohne Sell-Einschätzungen.
Für LivaNova plc sieht die Community ein Kursziel von 64 €, was eine erhebliche Steigerung um über 20% gegenüber dem aktuellen Kurs von 51.0 € bedeutet.
Was spricht für und gegen LivaNova plc in den nächsten Jahren?
Pro
?
M************
?
L*********** I********** f** d** n******* J****
?
W******* i* V********
Kontra
?
M****
?
U****************
?
A****************
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von LivaNova plc im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| LivaNova plc | - | 4,94 % | 0,00 % | 19,72 % | 8,97 % | -25,00 % | -17,74 % |
| Neogen Corp. | -2,65 % | 0,00 % | -21,99 % | -28,57 % | -39,89 % | -72,15 % | -57,43 % |
| Bio-Rad Labs Inc. A | 1,13 % | -2,42 % | -19,54 % | -37,00 % | -12,19 % | -51,81 % | - |
| Merit Medical Systems | 0,73 % | 2,22 % | -1,43 % | -6,12 % | 1,47 % | 33,98 % | 42,55 % |
Kommentare
LivaNova is a leader in Extra-Corporeal Membrane Oxygenation. A Theraphy that has established itself during Swineflue, Birdflue, SARS, MERS in the past. Well positioned as an Italian manufacturer the current Corona Epidemic will boost LivaNovas profits.
Strong expected performance in Cardiovascular Segment. Upside potential through treatment of Corona Virus with Extracorporeal Life Support. LivaNova is well positioned for that.
News
LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that its wholly-owned U.S. subsidiary, LivaNova USA, Inc., is providing notice to U.S. patients regarding a
LivaNova to Announce First-Quarter 2024 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2024 results on Wednesday, May 1, 2024 at 1 p.m. London time (8
LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its OSPREY clinical study, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation